Respiratory microbiome and clinical course of carbapenem-resistant Acinetobacter baumannii pneumonia in critically Ill patients

被引:1
|
作者
Yoon, Jin Gu [1 ]
Lim, Sooyeon [2 ,3 ]
Hyun, Hak-Jun [1 ]
Seong, Hye [1 ]
Noh, Ji Yun [1 ,2 ,3 ]
Song, Joon Young [1 ,2 ,3 ]
Kim, Woo Joo [1 ,2 ,3 ]
Cheong, Hee Jin [1 ,2 ,3 ]
机构
[1] Korea Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea
[2] Korea Univ, Coll Med, Asia Pacific Influenza Inst, Seoul, South Korea
[3] KU Med, Vaccine Innovat Ctr, Seoul, South Korea
关键词
Acinetobacter baumannii; intensive care units; microbiota; pneumonia; DISEASES SOCIETY; INFECTIONS; BACTERIA; AMERICA; HEALTH; IMPACT;
D O I
10.1097/MD.0000000000038988
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia has been a serious problem in the intensive care unit (ICU). However, defined characteristics of respiratory microbiome in CRAB pneumonia are lacking nowadays. This study aimed to analyze respiratory microbiome of CRAB pneumonia compared to non-CRAB pneumonia and reveal the clinical significance of respiratory microbiome data in these patients. Patients diagnosed with severe pneumonia with mechanical ventilation were enrolled in the ICU of a tertiary care hospital. Respiratory specimens were collected on days 1, 4, 7, and 14 in each participant via tracheal aspiration. Clinical data and outcomes of each enrolled patient were collected via electronic medical records. Microbiome analysis was conducted with collected respiratory specimens undergone by next-generation sequencing of microbial 16S ribosomal DNA. Six CRAB pneumonia, 4 non-CRAB pneumonia and 5 healthy controls were enrolled. In CRAB pneumonia, CRAB was detected in 3 patients by sputum culture at day 1, while it was negative at day 1 and detected later in the others by follow-up sputum culture. Beta diversity plot analysis showed differences between each group. Shannon index was decreased markedly at day 4 in CRAB pneumonia compared to the others. Among CRAB pneumonia cases, 3 respiratory specimens were culture-negative, but positive by microbiome analysis. Lower respiratory microbiome in CRAB pneumonia had distinct characteristics and early loss of diversity compared to non-CRAB pneumonia, which might be related to poor clinical course. Moreover, CRAB acquisition and colonization would be predicted by preemptive microbiome analysis, which will contribute to effective infection control in the ICU.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Italy
    Zarrilli, R.
    Bagattini, M.
    Migliaccio, A.
    Esposito, E. P.
    Triassi, M.
    ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITA, 2021, 33 (05): : 401 - 409
  • [22] Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model
    Song, Joon Young
    Cheong, Hee Jin
    Lee, Jacob
    Sung, Ah Kyeong
    Kim, Woo Joo
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (01) : 33 - 39
  • [23] Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
    Park, Jae-Min
    Yang, Kyung-Sook
    Chung, You-Seung
    Lee, Ki-Byung
    Kim, Jeong-Yeon
    Kim, Sun-Bean
    Sohn, Jang-Wook
    Yoon, Young-Kyung
    ANTIBIOTICS-BASEL, 2021, 10 (08):
  • [24] Risk factors for progression to bacteremia among patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia in the Intensive Care Unit
    Niu, Haiming
    Shen, Xiaoqing
    Liang, Hongkai
    Wu, Guishen
    Cai, Shaoqing
    Shen, Qian
    Zhang, Kouxing
    Chen, Miaolian
    Li, Jianwei
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (11) : 1337 - 1346
  • [25] The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii
    Amat, T.
    Gutierrez-Pizarraya, A.
    Machuca, I.
    Gracia-Ahufinger, I.
    Perez-Nadales, E.
    Torre-Gimenez, A.
    Garnacho-Montero, J.
    Cisneros, J. M.
    Torre-Cisneros, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (06) : 630 - 634
  • [26] A global view on carbapenem-resistant Acinetobacter baumannii
    Mueller, Carina
    Reuter, Sandra
    Wille, Julia
    Xanthopoulou, Kyriaki
    Stefanik, Danuta
    Grundmann, Hajo
    Higgins, Paul G.
    Seifert, Harald
    MBIO, 2023, 14 (06)
  • [27] Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy
    Mezzatesta, M. L.
    D'Andrea, M. M.
    Migliavacca, R.
    Giani, T.
    Gona, F.
    Nucleo, E.
    Fugazza, G.
    Pagani, L.
    Rossolini, G. M.
    Stefani, S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (02) : 160 - 166
  • [28] Dynamic Gene Clusters Mediating Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates
    Selim, Samy
    Faried, Osama Ahmed
    Almuhayawi, Mohamed S.
    Mohammed, Osama A.
    Saleh, Fayez M.
    Warrad, Mona
    ANTIBIOTICS-BASEL, 2022, 11 (02):
  • [29] Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study
    Katip, Wasan
    Rayanakorn, Ajaree
    Oberdorfer, Peninnah
    Taruangsri, Puntapong
    Nampuan, Teerapong
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (08) : 1249 - 1255
  • [30] Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii
    Apisarnthanarak, Anucha
    Jitpokasem, Sumana
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (11) : 1235 - 1237